Clinical Trial Update: Pan-tumor MRD Study

View source ↗

Summary

Paradigm Health's Pan-tumor MRD study (NCT06605404) is currently recruiting across several solid tumor indications including bladder, esophageal, gastric and GE…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma
• Melanoma
• Muscle-invasive Bladder Cancer
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Snippet

Sponsor: Paradigm Health | Conditions: Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer | Status: RECRUITING